Search clinical trials for: Relapsed or refractory solid tumors

Total 218853 results

Prelude Therapeutics

Completed

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Adenoid Cystic Carcinoma | Refractory Chronic Myelomonocytic Leukemia | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Advanced Solid Tumors | Relapsed/Refractory Myelodysplasia | Relapsed...

United States
Bristol-Myers Squibb
Nektar Therapeutics

Terminated

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020)

Ewing Sarcoma | Ependymoma | Medulloblastoma | Neuroblastoma | Rhabdomyosarcoma | High-grade Glioma | Leukemia and Lymphoma | Miscellaneous Brain Tumors | Miscellaneous Solid Tumors | Relapsed, Refractory Malignant Neoplasms

United States, Australia, France, Germany, Italy, Spain
Sorrento Therapeutics, Inc.

Withdrawn

Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors

Solid Tumor, Adult | Refractory Cancer | Relapsed Solid Neoplasm
H. Lee Moffitt Cancer Center and Research Institute
Pediatric Cancer Foundation

Completed

Metformin in Children With Relapsed or Refractory Solid Tumors

Solid Tumors | Primary Brain Tumors

United States
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

Solid Tumor | Metastatic Cancer | Advanced Cancer

United States
I-Mab Biopharma Co. Ltd.

No longer available

Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001

Solid Tumor Metastatic Cancer Advanced Cancer
Blueprint Medicines Corporation

Completed

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

GIST

United States, Korea, Republic of, Netherlands, China, France, Spain, Italy, Belgium, United Kingdom, Singapore, Australia, Canada, Germany, Sweden, Hungary, Austria, Czechia, Poland
National Cancer Institute (NCI)

Withdrawn

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Hematopoietic and Lymphoid Cell Neoplasm | Lynch Syndrome | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central... and other conditions

United States, Canada
Revolution Medicines, Inc.
Sanofi

Active, not recruiting

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Solid Tumors

United States
Nektar Therapeutics

Terminated

A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL)

Melanoma | Sarcoma | Renal Cell Carcinoma | Colorectal Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Carcinoma | Merkel Cell Carcinoma

United States
Blueprint Medicines Corporation

Completed

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Gastrointestinal Stromal Tumors (GIST) | Other Relapsed or Refractory Solid Tumors

United States, United Kingdom, France, Korea, Republic of, Belgium, Germany, Italy, Netherlands, Poland, Spain
Sorrento Therapeutics, Inc.

Withdrawn

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Solid Tumor | Relapsed Solid Tumor | Refractory Tumor
University of Colorado, Denver
University of Kentucky

Completed

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

Refractory Solid Tumors | Relapsed Solid Tumors

United States
Enzon Pharmaceuticals, Inc.

Terminated

Study of EZN-2208 Pediatric Patients With Solid Tumors

Solid Tumors

United States
Fox Chase Cancer Center
Merck Sharp & Dohme LLC; Celgene

Terminated

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Nonsmall Cell Lung Cancer | Relapsed or Refractory Solid Tumors

United States
CytomX Therapeutics

Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Solid Tumor | Unresectable or Metastatic Melanoma

Korea, Republic of, United States, Netherlands, Spain, Australia
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center; Merck Sharp & Dohme LLC; Dana-Farber Cancer Institute and other collaborators

Completed

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Solid Tumors | Relapsed/Refractory Sarcomas

United States, Canada
Menarini Group

Terminated

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study (CD205SHUTTLE)

Metastatic Solid Tumors | Relapsed/Refractory Non-Hodgkin Lymphoma

Italy, Spain, Belgium, United Kingdom
Eli Lilly and Company
Children's Oncology Group

Completed

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Recurrent Tumor | Pediatric Solid Tumor | Refractory Tumor | CNS Malignancies

United States
AstraZeneca

Completed

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Lymphoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Malignant Solid Tumors

United States, Canada
H. Lee Moffitt Cancer Center and Research Institute
Novartis; Celgene Corporation

Completed

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Juvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditions

United States, Canada
Incyte Biosciences International Sàrl

Completed

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions

United States
St. Jude Children's Research Hospital
CURE Childhood Cancer, Inc.

Completed

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Melanoma | Lymphoma | Renal Cell Carcinoma | Ewing Sarcoma | Rhabdoid Tumor | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Germ Cell Tumor | Gastrointestinal Tumor | Hepatic Tumor | Clear Cell Carcinoma | Non-rhabdomyosarcoma

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Relapsed or Refractory Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Melanoma | Solid Tumor | Metastatic Melanoma | Neoplasm

United States, United Kingdom
SCRI Development Innovations, LLC
Novartis

Completed

Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Children's Oncology Group
National Cancer Institute (NCI); Pfizer

Completed

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Childhood Anaplastic Large Cell Lymphoma

United States, Canada
NewLink Genetics Corporation

Terminated

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors (D-1MT)

Melanoma | Breast Cancer | Pancreatic Cancer | Lung Cancer | Solid Tumors

United States
Emory University
Children's Healthcare of Atlanta

Completed

Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors (AflacST1402)

Renal Cell Carcinoma | Osteosarcoma | Rhabdoid Tumor | Neuroblastoma | Retinoblastoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Ewings Sarcoma | Non-rhabdomyosarcoma Soft Tissue Sarcoma | Germ Cell Tumors | Clear Cell Sarcoma

United States
CTI BioPharma

Withdrawn

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Lymphoma | Solid Tumor (Excluding CNS)

United States
National Cancer Institute (NCI)

Completed

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
Acrotech Biopharma Inc.
Axis Clinicals Limited

Terminated

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Relapsed/Refractory Solid Tumors/Hematological Malignancies

United States
Celgene

Terminated

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Neoplasm Metastasis

United States, Australia
Celgene

Completed

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Tumor Virus Infections | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Transitional Cell | Carcinoma, Pancreatic Ductal

Spain, United States, France, Netherlands
National Cancer Institute (NCI)

Completed

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Recurrent Lymphoplasmacytic Lymphoma | AIDS-Related Hodgkin Lymphoma

United States
TG Therapeutics, Inc.
SCRI Development Innovations, LLC

Completed

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Gastrointestinal Stromal Tumor (GIST)

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Advanced Solid Tumors | Relapsed/Refractory Lymphoma

United States
Washington University School of Medicine

Withdrawn

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Glioma | Osteosarcoma | Ependymoma | Medulloblastoma | Rhabdomyosarcoma | Wilms Tumor | Neuroectodermal Tumor | Ewing's Sarcoma
Millennium Pharmaceuticals, Inc.

Completed

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Multiple Myeloma | Advanced Solid Tumors

United States, Canada
Theodore Laetsch

Withdrawn

HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors

Sarcoma | Osteosarcoma | Sarcoma, Ewing | Neuroblastoma | Rhabdomyosarcoma | Desmoid

United States
Delta-Fly Pharma, Inc.

Completed

Phase I Study of Oral DFP-11207 in Solid Tumors

Cancer | Solid Tumors

United States
Pharmacyclics LLC.

Completed

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Breast Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer

United States
Millennium Pharmaceuticals, Inc.

Completed

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

Advanced Solid Tumors | Relapsed/Refractory Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Withdrawn

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Rhabdomyosarcoma | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Hepatoblastoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Recurrent Childhood Liver Cancer
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Terminated

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

Solid Tumors

United States, United Kingdom
National Cancer Institute (NCI)

Withdrawn

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Sarcoma | Lymphoma | Brain Neoplasms | Osteosarcoma | Wilm's Tumor

United States
University of California, San Francisco
Hyundai Hope On Wheels

Completed

Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors

Malignant Solid Tumor | Childhood Solid Tumor

United States
Bristol-Myers Squibb

Completed

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

United States, France, Spain, Germany
GlaxoSmithKline

Completed

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

Carcinoma, Renal Cell

United States, Australia

Search clinical trials for: Relapsed or refractory solid tumors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations